Tom Powles: Renal cancer highlights at ASCO24 – KIM1 biomarker data stands out

Toni Choueiri shared a post by Tom Powles, Director of Barts Cancer Center, on X and added:

“3 biomarker presentations in kidney cancer from 2 mRCC trials (CLEAR/KYN426) with Brian Rini, Robert Motzer and an adjuvant trial with KIM-1 by Laurence Albiges.

Discussion by Wenxin Xu from Dana-Farber Lank Center for Genitourinary Oncology.

Vincent is a rising star in biomarkers and first to report on KIM1 in RCC–Don’t miss his talk!”

Quoting Tom Powles‘ post:

“Renal cancer highlights at ASCO24.

KIM1 biomarker data (blood) stands out. KIM1 (TIM1-4 family) increases in kidney injury and is immune suppressive (Treg). Already used for nephrotoxicity.

Robert Motzer presented compelling data from adjuvant ipilimumab/nivolumab at AACR24. A second positive study would be meaningful?”

Source: Toni Choueiri/X and Tom Powles/X

Toni Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. He is the Medical Director of International Strategic Initiatives at Dana-Farber and past President of the Medical Staff at DFCI (2016-2018).